Quinapril Hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318599

CAS#: 82586-55-8 (HCl)

Description: Quinapril Hydrochloride is an angiotensin-converting enzyme inhibitor. Quinapril is a prodrug that is converted to its active metabolite, quinaprilat. Quinapril’s target catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a potent vasoconstrictor and thus preventing its formation causes vasodilation and an increased capillary blood volume.

Price and Availability


USD 250
USD 850

USD 450
USD 1250

USD 650
USD 1950

Quinapril Hydrochloride, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318599
Name: Quinapril Hydrochloride
CAS#: 82586-55-8 (HCl)
Chemical Formula: C25H31ClN2O5
Exact Mass:
Molecular Weight: 474.98
Elemental Analysis: C, 63.22; H, 6.58; Cl, 7.46; N, 5.90; O, 16.84

Related CAS #: 85441-61-8 (free base)   82586-55-8 (HCl)    

Synonym: Quinapril Hydrochloride; Accupril; Accuprin; Acequin; Korec;Accupril; CI 906; CI-906; PD 109452-2; PD-109,452-2; quinapril; quinapril hydrochloride;

IUPAC/Chemical Name: (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride


InChi Code: InChI=1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Stolarczyk M, Maślanka A, Apola A, Krzek J. Determination of losartan
potassium, quinapril hydrochloride and hydrochlorothiazide in pharmaceutical
preparations using derivative spectrophotometry and chromatographic-densitometric
method. Acta Pol Pharm. 2013 Nov-Dec;70(6):967-76. PubMed PMID: 24383320.

2: Hailu SA, Bogner RH. Complex effects of drug/silicate ratio, solid-state
equivalent pH, and moisture on chemical stability of amorphous quinapril
hydrochloride coground with silicates. J Pharm Sci. 2011 Apr;100(4):1503-15. doi:
10.1002/jps.22387. Epub 2010 Nov 24. PubMed PMID: 24081473.

3: Hailu SA, Bogner RH. Solid-state surface acidity and pH-stability profiles of
amorphous quinapril hydrochloride and silicate formulations. J Pharm Sci. 2010
Jun;99(6):2786-99. doi: 10.1002/jps.22051. PubMed PMID: 20091829.

4: Stanisz B, Paszun S, Strzyzycka N, Ptaszyński E. Influence of humidity and
hydroxypropyl cellulose, hydroxypropylmethyl cellulose, glyceryl behenate or
magnesium stearate on the degradation kinetics of quinapril hydrochloride in
solid phase. Acta Pol Pharm. 2010 Jan-Feb;67(1):99-102. PubMed PMID: 20210086.

5: Hailu SA, Bogner RH. Effect of the pH grade of silicates on chemical stability
of coground amorphous quinapril hydrochloride and its stabilization using
pH-modifiers. J Pharm Sci. 2009 Sep;98(9):3358-72. doi: 10.1002/jps.21767. PubMed
PMID: 19363809.

6: Stanisz B. Kinetics of degradation of quinapril hydrochloride in tablets.
Pharmazie. 2003 Apr;58(4):249-51. PubMed PMID: 12749406.

7: Guo Y, Byrn SR, Zografi G. Physical characteristics and chemical degradation
of amorphous quinapril hydrochloride. J Pharm Sci. 2000 Jan;89(1):128-43. PubMed
PMID: 10664545.

8: Owada A, Nonoguchi H, Terada Y, Marumo F, Tomita K. Effects of quinapril
hydrochloride in patients with essential hypertension and impaired renal
function. Clin Exp Hypertens. 1997 May;19(4):495-502. PubMed PMID: 9140710.

9: Miller MA, Texter M, Gmerek A, Robbins J, Shurzinske L, Canter D. Quinapril
hydrochloride effects on renal function in patients with renal dysfunction and
hypertension: a drug-withdrawal study. Cardiovasc Drugs Ther. 1994
Apr;8(2):271-5. PubMed PMID: 7918140.

10: Hausin RJ, Codding PW. Molecular and crystal structures of MDL27,467A
hydrochloride and quinapril hydrochloride, two ester derivatives of potent
angiotensin converting enzyme inhibitors. J Med Chem. 1991 Feb;34(2):511-7.
PubMed PMID: 1995872.

11: Rojanasthien N, Nasangiam N, Kumsorn B, Roongapinun S, Jengjareon A.
Pharmacokinetics and bioequivalence study of the two 20-mg quinapril
hydrochloride tablet formulations in healthy Thai male volunteers. J Med Assoc
Thai. 2008 May;91(5):739-46. PubMed PMID: 18672641.

12: Bhavar GB, Chatpalliwar VA, Patil DD, Surana SJ. Validated HPTLC Method for
Simultaneous Determination of Quinapril Hydrochloride and Hydrochlorothiazide in
a Tablet Dosage Form. Indian J Pharm Sci. 2008 Jul-Aug;70(4):529-31. doi:
10.4103/0250-474X.44612. PubMed PMID: 20046789; PubMed Central PMCID: PMC2792558.

13: Stanisz B. The influence of pharmaceutical excipients on quinapril
hydrochloride stability. Acta Pol Pharm. 2005 May-Jun;62(3):189-93. PubMed PMID:

14: Stanisz B. The stability of quinapril hydrochloride--a mixture of amorphous
and crystalline forms (QHCl-AC)--in solid phase. Acta Pol Pharm. 2003
Nov-Dec;60(6):443-9. PubMed PMID: 15080591.

15: Guo Y, Byrn SR, Zografi G. Effects of lyophilization on the physical
characteristics and chemical stability of amorphous quinapril hydrochloride.
Pharm Res. 2000 Aug;17(8):930-5. PubMed PMID: 11028937.

16: McGuire EJ, Anderson JA, Gough AW, Herman JR, Pegg DG, Theiss JC, de la
Iglesia FA. Preclinical toxicology studies with the angiotensin-converting enzyme
inhibitor quinapril hydrochloride (Accupril). J Toxicol Sci. 1996
Nov;21(4):207-14. Review. PubMed PMID: 8959644.